{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:10:53Z","timestamp":1790269853104,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T00:00:00Z","timestamp":1524700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1038\/s41375-018-0133-x","type":"journal-article","created":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T08:19:57Z","timestamp":1524730797000},"page":"1404-1413","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["A predictive model for risk of early grade\u2009\u2265\u20093 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial"],"prefix":"10.1038","volume":"32","author":[{"given":"Charles","family":"Dumontet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Belch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rodon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Van Droogenbroeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Van de Velde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Lahuerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Allangba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Attal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murielle","family":"Roussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Yves","family":"Mary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Civet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Tinel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Gaston-Math\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,26]]},"reference":[{"key":"133_CR1","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1086\/605664","volume":"49","author":"M Nucci","year":"2009","unstructured":"Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009;49:1211\u201325.","journal-title":"Clin Infect Dis"},{"key":"133_CR2","doi-asserted-by":"publisher","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","volume":"23","author":"BM Augustson","year":"2005","unstructured":"Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002\u2014Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23:9219\u201326.","journal-title":"J Clin Oncol"},{"key":"133_CR3","doi-asserted-by":"publisher","first-page":"e2305","DOI":"10.1097\/MD.0000000000002305","volume":"94","author":"P Hsu","year":"2015","unstructured":"Hsu P, Lin TW, Gau JP, Yu YB, Hsiao LT, Tzeng CH, et al. Risk of early mortality in patients with newly diagnosed multiple myeloma. Med (Baltim). 2015;94:e2305.","journal-title":"Med (Baltim)"},{"key":"133_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3324\/haematol.2014.107714","volume":"100","author":"C Blimark","year":"2015","unstructured":"Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107\u201313.","journal-title":"Haematologica"},{"key":"133_CR5","doi-asserted-by":"crossref","first-page":"46593","DOI":"10.18632\/oncotarget.16235","volume":"8","author":"L Ying","year":"2017","unstructured":"Ying L, YinHui T, Yunliang Z, Sun H. Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis. Oncotarget. 2017;8:46593\u2013600.","journal-title":"Oncotarget"},{"key":"133_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2016.07.025","volume":"67","author":"BW Teh","year":"2016","unstructured":"Teh BW, Harrison SJ, Worth LJ, Thursky KA, Slavin MA. Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: a systematic review and meta-analysis. Eur J Cancer. 2016;67:21\u201337.","journal-title":"Eur J Cancer"},{"key":"133_CR7","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371:906\u201317.","journal-title":"N Engl J Med"},{"key":"133_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","volume":"131","author":"T Facon","year":"2018","unstructured":"Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018;131:301\u201310.","journal-title":"Blood"},{"key":"133_CR9","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","volume":"14","author":"J San Miguel","year":"2013","unstructured":"San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055\u201366.","journal-title":"Lancet Oncol"},{"key":"133_CR10","doi-asserted-by":"publisher","first-page":"4445","DOI":"10.1182\/blood-2008-02-141614","volume":"112","author":"M Wang","year":"2008","unstructured":"Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood. 2008;112:4445\u201351.","journal-title":"Blood"},{"key":"133_CR11","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123\u201332.","journal-title":"N Engl J Med"},{"key":"133_CR12","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"DM Weber","year":"2007","unstructured":"Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133\u201342.","journal-title":"N Engl J Med"},{"key":"133_CR13","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","volume":"366","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366:1759\u201369.","journal-title":"N Engl J Med"},{"key":"133_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev.publhealth.20.1.145","volume":"20","author":"LD Fisher","year":"1999","unstructured":"Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health. 1999;20:145\u201357.","journal-title":"Annu Rev Public Health"},{"key":"133_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/BF02294359","volume":"52","author":"H Akaike","year":"1987","unstructured":"Akaike H. Factor analysis and AIC. Psychometrika. 1987;52:317\u201332.","journal-title":"Psychometrika"},{"key":"133_CR16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"133_CR17","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u2013548.","journal-title":"Lancet Oncol"},{"key":"133_CR18","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/0002-9343(81)90303-X","volume":"71","author":"RT Perri","year":"1981","unstructured":"Perri RT, Hebbel RP, Oken MM. Influence of treatment and response status on infection risk in multiple myeloma. Am J Med. 1981;71:935\u201340.","journal-title":"Am J Med"},{"key":"133_CR19","first-page":"517","volume":"79","author":"HC Rayner","year":"1991","unstructured":"Rayner HC, Haynes AP, Thompson JR, Russell N, Fletcher J. Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single centre between 1975 and 1988. Q J Med. 1991;79:517\u201325.","journal-title":"Q J Med"},{"key":"133_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","volume":"138","author":"G Pratt","year":"2007","unstructured":"Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol. 2007;138:563\u201379.","journal-title":"Br J Haematol"},{"key":"133_CR21","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.3389\/fimmu.2017.01247","volume":"8","author":"BW Teh","year":"2017","unstructured":"Teh BW, Harrison SJ, Allison CC, Slavin MA, Spelman T, Worth LJ, et al. Predicting risk of infection in patients with newly diagnosed multiple myeloma: utility of immune profiling. Front Immunol. 2017;8:1247.","journal-title":"Front Immunol"},{"key":"133_CR22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/bjh.13532","volume":"171","author":"BW Teh","year":"2015","unstructured":"Teh BW, Harrison SJ, Worth LJ, Spelman T, Thursky KA, Slavin MA. Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Br J Haematol. 2015;171:100\u20138.","journal-title":"Br J Haematol"},{"key":"133_CR23","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32:587\u2013600.","journal-title":"J Clin Oncol"},{"key":"133_CR24","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","volume":"100","author":"E Terpos","year":"2015","unstructured":"Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100:1254\u201366.","journal-title":"Haematologica"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0133-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0133-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0133-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:34:29Z","timestamp":1684618469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-018-0133-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,26]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["133"],"URL":"https:\/\/doi.org\/10.1038\/s41375-018-0133-x","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,26]]},"assertion":[{"value":"13 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Charles Dumontet has received honoraria from Sanofi and Janssen, has received fees for a consulting\/advisory role from Merck, and has received research funding from Roche. Cyrille Hulin has received honoraria from Celgene, Amgen, Bristol-Myers Squibb, Novartis, Janssen-Cilag, and Takeda. Meletios A. Dimopoulos has received honoraria from Amgen, Celgene, Janssen, and Takeda and has received fees for a consulting\/advisory role from Amgen, Celgene, Janssen, and Takeda. Angela Dispenzieri has received research funding from Alnylam, Celgene, Pfizer, Prothena, and Takeda. Heinz Ludwig has received speakers\u2019 bureau fees from Celgene, Janssen, Takeda, and Amgen and has received research funding from Takeda and Amgen. Michele Cavo has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, and Takeda. Juan Jos\u00e9 Lahuerta has received fees for a consulting\/advisory role from Celgene, Janssen, and Takeda. Olivier Allangba has received fees for a consulting\/advisory role from Novartis and has received travel, accommodations, and expenses from Takeda, Pfizer, Celgene, Amgen, and Roche. Eileen Boyle has received fees for a consulting\/advisory role from Celgene. Aurore Perrot has received honoraria and fees for a consulting\/advisory role from Celgene, Janssen, Takeda, and Bristol-Myers Squibb. Philippe Moreau has received honoraria from Celgene, Takeda, Novartis, Amgen, and Janssen-Cilag and has received fees for a consulting\/advisory role from Celgene, Takeda, Novartis, Amgen, and Janssen. Murielle Roussel has received research funding from Amgen, Celgene, and Janssen. Mohamad Mohty has received honoraria from Celgene, Janssen, Bristol-Myers Squibb, Takeda, Novartis, and Amgen; fees for consulting\/advisory role from Celgene, Janssen, Bristol-Myers Squibb, Takeda, Novartis, and Amgen; speakers\u2019 bureau fees from Janssen and Sanofi; research funding from Sanofi; and travel, accommodations, expenses from Sanofi, JAZZ, Novartis, Janssen, and Amgen. Alexandre Civet has received fees for a consulting\/advisory role from Celgene. Bruno Costa is an employee of and owns stock in Celgene. Antoine Tinel is an employee of and owns stock in Celgene. Yann Gaston-Math\u00e9 is an employee of IntegraGen, has received fees for a consulting\/advisory role from Celgene, and has received travel, accommodations, expenses from Celgene. Thierry Facon has received fees for a consulting\/advisory role from Amgen, Celgene, Janssen, Karyopharm, PharmaMar, and Takeda and has received speakers\u2019 bureau fees from Amgen, Celgene, Janssen, and Takeda. Andrew Belch, Philippe Rodon, Jan Van Droogenbroeck, Lugui Qiu, Ann Van de Velde, Jae Hoon Lee, Salomon Manier, Michel Attal, and Jean Yves Mary declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}